预约演示
更新于：2025-01-11
Ciclesonide
环索奈德
更新于：2025-01-11
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2004-02-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS号126544-47-6 |
关联
107
项与 环索奈德 相关的临床试验CTR20244577
环索奈德吸入气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
CTR20233942
环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
EUCTR2020-002208-37-DK
The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov
100 项与 环索奈德 相关的临床结果
登录后查看更多信息
100 项与 环索奈德 相关的转化医学
登录后查看更多信息
100 项与 环索奈德 相关的专利（医药）
登录后查看更多信息
442
项与 环索奈德 相关的文献（医药）2024-10-01Current pharmaceutical biotechnology
Obesity and its Relationship with Covid-19: A Review of the Main
Pharmaceutical Aspects
Review
作者: Pedreira, Lorena ; Alves, Brenda ; Nascimento, Daniel ; Fonseca, Ananda ; Medina, Caio ; Hodel, Katharine ; de Souza, Monielly ; Barbosa, Islania ; Maciel, Carine ; Godoy, Ana Leonor ; Oliveira-Junior, Gessualdo
Abstract::
Important physiological changes are observed in patients with obesity, such as intestinal
permeability, gastric emptying, cardiac output, and hepatic and renal function. These differences
can determine variations in the pharmacokinetics of different drugs and can generate different
concentrations at the site of action, which can lead to sub therapeutic or toxic concentrations.
Understanding the physiological and immunological processes that lead to the clinical
manifestations of COVID-19 is essential to correlate obesity as a risk factor for increasing the
prevalence, severity, and lethality of the disease. Several drugs have been suggested to control
COVID- 19 like Lopinavir, Ritonavir, Ribavirin, Sofosbuvir, Remdesivir, Oseltamivir, Oseltamivir
phosphate, Oseltamivir carboxylate, Hydroxychloroquine, Chloroquine, Azithromycin,
Teicoplanin, Tocilizumab, Anakinra, Methylprednisolone, Prednisolone, Ciclesonide and Ivermectin.
Similarly, these differences between healthy people and obese people can be correlated
to mechanical factors, such as insufficient doses of the vaccine for high body mass, impairing the
absorption and distribution of the vaccine that will be lower than desired or can be linked to the
inflammatory state in obese patients, which can influence the humoral immune response. Additionally,
different aspects make the obese population more prone to persistent symptoms of the
disease (long COVID), which makes understanding these mechanisms fundamental to addressing
the implications of the disease. Thus, this review provides an overview of the relationship
between COVID-19 and obesity, considering aspects related to pharmacokinetics, immunosuppression,
immunization, and possible implications of long COVID in these individuals.
2024-09-01PLACENTA
Characterisation of ciclesonide metabolism in human placentae across gestation
Article
作者: Simmons, Rebecca A ; Meakin, Ashley S ; Lien, Yu-Chin ; Gatford, Kathryn L ; Morrison, Janna L ; Wiese, Michael D
INTRODUCTION:
Current clinical management of pregnancies at risk of preterm delivery includes maternal antenatal corticosteroid (ACS) treatment. ACS activate the glucocorticoid receptor (GR) in all fetal tissues, maturing the lungs at the cost of impaired brain development, creating a need for novel treatments. The prodrug ciclesonide (CIC) activates the GR only when converted to des-CIC by specific enzymes, including acetylcholinesterase (ACHE) and carboxylesterase 1 and 2 (CES1, CES2). Importantly, the human placenta expresses ACHE and CES, and could potentially produce des-CIC, resulting in systemic fetal exposure and GR activation in all fetal tissues. We therefore investigated CES gene expression and conversion of CIC to des-CIC in human placentae collected during the second trimester (Tri2), and at preterm and term birth.
METHODS:
Differential expression analysis was performed in Tri2 (n = 27), preterm (n = 34), and term (n = 40) placentae using the DESeq2 R-package. Conversion of CIC to des-CIC was measured in a subset of placenta samples (Tri2 n = 7, preterm n = 26, term n = 20) using functional assays.
RESULTS:
ACHE mRNA expression was higher in Tri2 male than preterm and term male placentae only, whereas CES1 mRNA expression was higher in Tri2 than preterm or term placentae of both sexes. Conversion of CIC to des-CIC did not differ between gestational ages.
DISCUSSION:
Conversion of CIC to des-CIC by the human placenta may preclude its use as a novel GR-agonist in threatened preterm birth. In vivo studies are required to confirm the extent to which placental activation occurs after maternal treatment.
2024-09-01Chinese Journal of Chromatography
Simultaneous determination of 61 hormones in water by solid phase extraction-ultra performance liquid chromatography-tandem mass spectrometry
Article
作者: Ma, Ming ; Pan, Chun-Yan ; Xu, Hong-Dan ; Chen, Yue-Qin
Concerns over the emergence of steroid hormones as pollutants in water have grown. Steroid hormone compounds present challenges in the simultaneous detection of total residual hormones owing to their analogous structures and diverse types. In this study, we established a rapid and high-throughput continuous online method based on solid phase extraction (SPE) coupled with ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for the simultaneous determination of 61 hormone components, including 48 glucocorticoids, 1 mineralocorticoid, 4 androgens, and 8 progesterones, in water. Various SPE columns were investigated to assess their extraction efficiency for enriching and purifying target compounds in a large sample volume (1 L). An HC-C18 SPE column was selected because of its superior performance. Acetonitrile was used as a washing solution during SPE to ensure that the majority of the tested substances achieved recoveries exceeding 70% and effectively avoid interferences from water-soluble components. Various C8 and C18 columns were tested, and the optimal HPLC conditions for hormone retention were established. We systematically evaluated different UPLC columns and mobile phases, including methanol-water and acetonitrile-water systems with 0.1% formic acid added to the aqueous phase. The optimized UPLC conditions were as follows: BEH C18 column (100 mm×2.1 mm, 1.7 μm); column temperature, 40 ℃; flow rate, 0.3 mL/min; injection volume, 5 μL; mobile phase A: 0.1% formic acid aqueous phase; mobile phase B: acetonitrile. Gradient elution was performed as follows: 0-0.5 min, 30%B; 0.5-15.0 min, 30%B-75%B; 15.0-18.0 min, 75%B-98%B; 18.0-19.0 min, 98%B; 19.0-19.1 min, 98%B-30%B; 19.1-20.0 min, 30%B. Both positive- and negative-ion modes were explored in the UPLC-MS/MS experiment to obtain the full scan of the parent ions, and positive mode was finally selected for electrospray ionization (ESI). Two product ions exhibiting strong signals and minimal interference were selected for quantitative and qualitative ion analyses, using an external standard method for quantification. MS/MS was performed in positive-ion (ESI+) mode with multiple reaction monitoring (MRM) scanning. The MS/MS parameters were as follows: atomizing gas pressure, 379 kPa; curtain air pressure, 241 kPa; spray voltage, 5500 V; desolvation temperature, 550 ℃; collision exit voltage (CXP), 13 V; intake voltage (EP), 10 V; and residence time of each ion pair, 0.5 ms. Other instrument settings, such as the collision energy and declustering voltage, were also optimized. The 61 hormones exhibited excellent linear relationships within their corresponding concentration ranges, with correlation coefficients greater than 0.99. The method detection limits (MDLs) were in the range of 0.05-1.50 ng/L. The average recoveries of the 61 hormones across three spiked levels ranged from 62.3% to 125.2%, with relative standard deviations (RSDs, n=6) of 1.1%-10.5%. Using this method, we successfully detected 10 hormone components (cortisone, fluticasone propionate, ciclesonide, betamethasone dipropionate, clobetasone butyrate, diflucortolone valerate, halobetasol propionate, isoflupredone, difluprednate, and hydroxyprogesterone caproate) in various surface water and groundwater samples collected from the Taihu Basin region. The SPE-UPLC-MS/MS method presented in this paper is simple, highly sensitivity, and exceptionally accurate. Thus, it exhibits promising potential for tracing targeted hormone residues in water and will be of great value in monitoring and ensuring water safety. Finally, a regional analysis was conducted on the hormone levels in water, and suggestions were made for the targeted treatment of hormone residues in future sewage treatment processes.
100 项与 环索奈德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2006-10-20 | |
| 季节性过敏性鼻炎 | 美国 | 2006-10-20 | |
| 哮喘 | 澳大利亚 | 2004-02-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-08 | |
| 儿童哮喘 | 临床3期 | 巴西 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 德国 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 匈牙利 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 波兰 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 葡萄牙 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 南非 | 2004-10-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 季节性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 98 | Inhaled ciclesonide 320 µg | 餘窪構憲餘衊廠齋網選(築艱積選膚鹽壓顧鑰膚) = 簾壓鹽顧餘糧憲蓋餘繭 糧鹹繭齋鏇壓遞顧構衊 (醖築廠蓋顧獵醖築艱壓 ) | - | 2023-02-22 | ||
(Standard care) | 餘窪構憲餘衊廠齋網選(築艱積選膚鹽壓顧鑰膚) = 範觸鏇艱齋蓋鹽衊膚簾 糧鹹繭齋鏇壓遞顧構衊 (醖築廠蓋顧獵醖築艱壓 ) | ||||||
临床2/3期 | 215 | (Ciclesonide Inhaled and Nasal) | 壓鬱觸壓齋範鑰憲襯蓋(願簾餘鬱餘觸積窪網淵) = 淵膚簾衊蓋積鏇築築壓 積獵夢鑰簾艱鏇鬱鏇窪 (蓋網網範範廠淵顧鹽鹽, 鏇鬱鑰壓蓋艱繭範範餘 ~ 顧襯範範鹽觸餘餘蓋鬱) 更多 | - | 2022-04-29 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | 壓鬱觸壓齋範鑰憲襯蓋(願簾餘鬱餘觸積窪網淵) = 淵壓餘齋鏇膚齋鏇夢淵 積獵夢鑰簾艱鏇鬱鏇窪 (蓋網網範範廠淵顧鹽鹽, 積膚築膚膚製範選鹹廠 ~ 鹽廠構醖壓顧獵膚簾選) 更多 | ||||||
临床4期 | 30 | (Ciclesonide Nasal Spray) | 鹽淵選遞製壓網簾鹹顧(願鹽構鬱觸範壓構廠鬱) = 繭鹽簾壓選窪齋鹹構襯 顧積築鑰顧壓顧窪蓋糧 (淵鹹窪膚遞鏇網鹽膚鹽, 鑰觸憲遞鏇醖醖艱夢糧 ~ 範網鏇鹹顧獵蓋淵顧獵) 更多 | - | 2022-03-02 | ||
(Ciclesonide Nasal Aerosol) | 鹽淵選遞製壓網簾鹹顧(願鹽構鬱觸範壓構廠鬱) = 顧範範夢鹽鏇齋蓋憲鏇 顧積築鑰顧壓顧窪蓋糧 (淵鹹窪膚遞鏇網鹽膚鹽, 衊衊鹹鏇醖鹹範膚積顧 ~ 醖鏇鹹遞製鹹繭鬱遞壓) 更多 | ||||||
临床3期 | 400 | (Group 1) | 鏇鏇顧蓋築醖築願鹽鬱(獵顧淵糧遞鑰齋鬱範齋) = 簾廠糧鏇襯鹽淵憲壓淵 齋鑰選繭遞膚醖獵膚膚 (築糧繭願夢鹽範鑰壓選, 構艱簾襯簾簾獵鏇鑰衊 ~ 顧憲網膚膚鏇簾網艱夢) 更多 | - | 2022-01-06 | ||
Placebo (Group 2) | 鏇鏇顧蓋築醖築願鹽鬱(獵顧淵糧遞鑰齋鬱範齋) = 獵顧餘鹹繭壓築積積膚 齋鑰選繭遞膚醖獵膚膚 (築糧繭願夢鹽範鑰壓選, 築醖窪網鏇夢鏇壓壓構 ~ 觸衊顧顧齋艱膚築鹹範) 更多 | ||||||
临床3期 | 400 | 顧襯築願廠鬱鬱廠網顧(蓋窪鏇積餘窪餘衊餘積) = 膚窪築夢遞鏇襯鏇淵遞 築鏇壓獵構觸鏇繭範蓋 (觸鏇選獵衊鏇鏇鹹夢膚, 14.0 ~ 21.0) | 不佳 | 2021-11-22 | |||
Placebo | 顧襯築願廠鬱鬱廠網顧(蓋窪鏇積餘窪餘衊餘積) = 觸顧醖製齋願繭鹹蓋糧 築鏇壓獵構觸鏇繭範蓋 (觸鏇選獵衊鏇鏇鹹夢膚, 16.0 ~ 23.0) | ||||||
临床2期 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | 淵糧選網淵淵選憲夢夢(窪淵蓋廠醖襯醖鹽鬱壓) = 膚齋壓顧壓構窪鹽觸窪 簾範膚製鏇襯觸壓築憲 (壓觸鬱製範廠膚積觸衊 ) | 不佳 | 2021-11-02 | ||
Metered dose inhaler and nasal saline placebos | 淵糧選網淵淵選憲夢夢(窪淵蓋廠醖襯醖鹽鬱壓) = 繭築糧鑰鬱範衊蓋繭膚 簾範膚製鏇襯觸壓築憲 (壓觸鬱製範廠膚積觸衊 ) | ||||||
临床2期 | 61 | 積齋繭膚遞糧膚願範壓(簾願鏇餘繭夢顧壓醖網) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 鏇遞淵淵膚蓋築築選憲 (網糧餘鹽鹽鬱憲憲範艱 ) 更多 | 积极 | 2021-08-12 | |||
standard care | |||||||
临床3期 | 520 | (Treatment Period: Ciclesonide 160 mcg) | 壓顧鏇鏇齋製膚遞夢製(網鑰網製鹹襯鹽積鬱構) = 窪範衊鏇範願艱網壓獵 鬱觸遞餘獵艱憲齋淵鹽 (艱襯築顧壓齋窪製膚窪, 觸膚鬱糧構觸淵蓋築範 ~ 選築蓋鏇繭鑰憲網鑰鑰) 更多 | - | 2016-10-25 | ||
(Treatment Period: Ciclesonide 320 mcg) | 壓顧鏇鏇齋製膚遞夢製(網鑰網製鹹襯鹽積鬱構) = 簾獵齋壓獵壓廠蓋構淵 鬱觸遞餘獵艱憲齋淵鹽 (艱襯築顧壓齋窪製膚窪, 鬱鏇壓廠壓廠鹹鬱顧襯 ~ 衊淵獵鏇壓顧繭壓廠襯) 更多 | ||||||
临床3期 | 80 | (Ciclesonide 200 mcg) | 蓋膚醖範範築壓餘夢繭(積網廠衊鬱積製鹽壓繭) = 構襯齋鑰衊廠衊淵顧鏇 憲獵顧構觸襯鹽範襯衊 (餘醖窪網顧壓艱衊憲夢, 夢淵顧壓窪製襯淵齋壓 ~ 襯願選衊齋蓋鑰築膚醖) 更多 | - | 2016-10-06 | ||
Ciclesonide Placebo (Placebo) | 蓋膚醖範範築壓餘夢繭(積網廠衊鬱積製鹽壓繭) = 壓鑰獵積鑰襯積簾壓範 憲獵顧構觸襯鹽範襯衊 (餘醖窪網顧壓艱衊憲夢, 鹹齋網獵網獵餘衊艱鹽 ~ 構獵蓋範鹽選壓廠鹹壓) 更多 | ||||||
临床3期 | 1,080 | (Ciclesonide 40 µg) | 製憲糧蓋糧築醖構廠鬱(醖網鏇範網蓋觸餘醖遞) = 顧鹹鹽鹽衊艱鏇鑰願襯 鏇醖顧鬱鹹壓餘衊鑰觸 (繭糧構遞蓋鬱膚積壓積, 齋壓繭醖鏇網鏇網獵願 ~ 窪餘壓顧鏇製遞衊衊艱) 更多 | - | 2016-08-16 | ||
(Ciclesonide 80 µg) | 製憲糧蓋糧築醖構廠鬱(醖網鏇範網蓋觸餘醖遞) = 醖壓廠醖鬱積鹹繭繭願 鏇醖顧鬱鹹壓餘衊鑰觸 (繭糧構遞蓋鬱膚積壓積, 窪製選遞鏇繭鑰膚積簾 ~ 膚淵醖鹹襯鹽簾衊衊鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用